截至2025年12月22日收盘，联影医疗（688271）报收于128.4元，较前一交易日上涨0.83%，最新总市值 为1058.22亿元。该股当日开盘127.79元，最高128.42元，最低126.72元，成交额达3.99亿元，换手率为 0.38%。 近日，联影医疗发布关于召开2025年第一次临时股东会的会议资料，其中包含《关于2026年度日常关联 交易预计的议案》。根据公告，本次会议将审议公司2026年度与关联方之间的日常关联交易计划，涉及 向关联方采购原材料、销售产品、提供劳务、接受服务及商标授权许可等事项，预计2026年度总交易金 额为105,707.65万元。各类别交易的具体金额及占比已在议案中列明。会议将采用现场与网络投票相结 合的方式进行，现场会议定于2025年12月30日举行。 最新公告列表 《联影医疗2025年第一次临时股东会会议资料》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

上海联影医疗科技股份有限公司 2025 年第一次临时股东会会议资料 上海联影医疗科技股份有限公司 2025 年第一次临时股东会 会议资料 二〇二五 年 十二 月 上海联影医疗科技股份有限公司 2025 年第一次临时股东会会议资料 上海联影医疗科技股份有限公司 2025 年第一次临时股东会会议资料目录 一、2025 年第一次临时股东会会议议程 二、2025 年第一次临时股东会须知 三、2025 年第一次临时股东会会议议案 1、《关于 2026 年度日常关联交易预计的议案》 上海联影医疗科技股份有限公司 2025 年第一次临时股东会会议资料 上海联影医疗科技股份有限公司 2025 年第一次临时股东会会议议程 召开方式：现场投票表决与网络投票表决相结合 现场会议召开时间：2025 年 12 月 30 日下午 14:00 网络投票时间：2025 年 12 月 30 日 为了维护全体股东的合法权益，确保公司股东会顺利召开，根据中国证券 监督管理委员会《上市公司股东会规则》和《公司章程》的有关规定，特制定 股东会须知如下： 一、为确认出席大会的股东或其代理人及其他出席者的出席资格，会议工 作人员将对出席会议者的身份进行必 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

10% 医药生物 沪深300 医药生物行业 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/12/5-2025/12/18） 29 省耗材联盟集采启动 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 行 业 研 医药生物（申万）指数走势 -35% 资料来源：iFind，东莞证券研究所 -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 相关报告 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% -35% -30% -25% -20% -15% -10% -5% 0% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 12 月 19 日 分析师：谢雄雄 SAC 执业证书编号： S0 ...

2025年度武汉投资促进大会现场。 18日，"投资武汉 共赢未来"2025年度武汉投资促进大会在武汉会议中心开幕。 THOUS 一元物CEO、创新 Ta 本次大会共邀请世界500强企业代表、大型跨国公司代表、科技创新型企业代表，其他知名企业及商协会代表等约240人参加，畅叙合 作、共谋发展。现场共签约产业项目160个，签约金额1109.7亿元，涵盖人工智能、新一代信息技术、大健康和生物制造、数字经济、光电 子信息、智能网联汽车、新能源、新材料、高端装备制造等多个产业领域。 2025年度武汉投资促进大会台下嘉宾。 会上，零一万物CEO、创新工厂董事长李开复，蔚来创始人、董事长兼CEO李斌通过视频的形式为大会送上祝福。联影集团董事长薛 敏，绿城中国执行总裁赵晖，安波福电气分配系统事业部副总裁兼中国区董事长祁松，千寻智能（杭州）科技有限公司创始人兼首席执行 官韩峰涛，星巴克企业管理（中国）有限公司副总裁周海冰，北京瑞莱智慧科技有限公司首席执行官田天先后作交流发言。 此外，大会还举办了以人工智能、生物制造、数字经济及城市更新发展为主题的四场专题对接活动，为加快建设国家中心城市、全力 打造"五个中心"、全面建设现代化大 ...

（编辑 任世碧） 证券日报网讯 12月18日晚间，浩瀚深度发布公告称，公司于2025年12月17日收到冯彦军先生出具的 《关于减持计划时间届满暨减持结果的告知函》，本次减持计划期限届满，冯彦军先生没有减持公司股 票。 ...

Investment Rating - The report maintains a "Positive" investment rating for the medical device industry [3]. Core Insights - The medical device industry is expected to return to positive growth in 2025 after two consecutive years of decline in 2023 and 2024, driven by increased demand for hospital equipment due to equipment renewal policies [10]. - Monthly procurement data shows a continuous recovery trend, with November 2025 procurement amounting to 208.76 billion yuan, reflecting a month-on-month increase of 26.93% [18]. - The domestic production rate of medical devices has increased from 19% in 2019 to 48% in November 2025, indicating a significant shift towards local manufacturing [21]. Summary by Sections Equipment Procurement - The medical device procurement is showing a sustained recovery, with a projected annual procurement scale for 2025 estimated between 1,884 billion yuan and 2,422 billion yuan based on the first half's performance [14]. - The procurement amount for November 2025 was 208.76 billion yuan, with a year-on-year decrease of 0.25% but a month-on-month increase of 26.93% [18]. Market Segmentation - The procurement scale for ultrasound devices in November 2025 reached 22.40 billion yuan, showing a year-on-year growth of 17.60% and a month-on-month growth of 41.67% [27]. - CT device procurement in November 2025 was 25.36 billion yuan, with a year-on-year increase of 27.58% and a month-on-month increase of 22.82% [28]. - MRI procurement in November 2025 was 23.94 billion yuan, reflecting a year-on-year growth of 5.68% and a month-on-month growth of 29.94% [31]. - Digestive endoscope procurement in November 2025 was 7.30 billion yuan, with a year-on-year increase of 3.26% and a month-on-month increase of 41% [36]. - Surgical robot procurement in November 2025 was 5.60 billion yuan, showing a year-on-year growth of 8.33% but a month-on-month decrease of 11.53% [37]. Company Performance - Mindray Medical's procurement in November 2025 was 13.18 billion yuan, with a year-on-year increase of 12.16% and a month-on-month increase of 38.34% [44]. - United Imaging's procurement in November 2025 reached 14.33 billion yuan, reflecting a year-on-year growth of 30.40% and a month-on-month growth of 31.15% [46]. - KAILI Medical's procurement in November 2025 was 2.47 billion yuan, with a year-on-year increase of 62.15% and a month-on-month increase of 17.95% [50]. - Aohua Endoscopy's procurement in November 2025 was 1.09 billion yuan, showing a year-on-year growth of 59.95% and a month-on-month growth of 62.14% [54].

Core Viewpoint - The stock of United Imaging Healthcare (688271) has shown a slight increase in price, with significant fluctuations in capital flow, indicating mixed investor sentiment and potential opportunities for analysis [1][2]. Group 1: Stock Performance - As of December 17, 2025, United Imaging Healthcare closed at 127.46 yuan, up 0.21% with a turnover rate of 0.43% and a trading volume of 35,100 hands, resulting in a transaction amount of 445 million yuan [1]. - Over the past five days, the stock has experienced varying price changes, with a notable drop of 2.01% on December 16, 2025, and a significant increase of 75.41% in revenue for the third quarter of 2025 [2][3]. Group 2: Capital Flow Analysis - On December 17, 2025, the net outflow of main funds was 38.97 million yuan, accounting for 8.75% of the total transaction amount, while retail investors saw a net inflow of 43.88 million yuan, representing 9.85% of the total [1][2]. - The five-day capital flow data indicates a trend of fluctuating net inflows and outflows among different investor categories, with retail investors showing resilience in their investment [2]. Group 3: Financial Metrics and Industry Ranking - United Imaging Healthcare has a total market value of 105.05 billion yuan, significantly higher than the industry average of 10.78 billion yuan, ranking 2nd among 125 companies in the medical device sector [3]. - The company reported a net profit of 1.12 billion yuan for the third quarter of 2025, reflecting a year-on-year increase of 143.8%, with a gross margin of 47.02% [3]. - The company's price-to-earnings ratio (P/E) stands at 70.33, which is lower than the industry average of 75.83, indicating a competitive valuation [3].

Core Insights - Shanghai United Imaging Healthcare Co., Ltd. has won a bid for a high-end CT procurement project in Wenshan Zhuang and Miao Autonomous Prefecture, with a contract amount of 10.8 million [1][2]. Company Overview - Shanghai United Imaging Healthcare Co., Ltd. has invested in 21 companies and participated in 8,581 bidding projects [1]. - The company holds 915 trademark registrations, 5,568 patents, and 109 copyrights, along with 457 administrative licenses [1]. Project Details - The procurement was announced by the Wenshan Zhuang and Miao Autonomous Prefecture Health Commission on December 15, 2025 [2]. - The project involves the procurement of a 256-slice ultra-high-end CT system [1].

Core Viewpoint - The recent announcement by Moer Thread to manage idle fundraising of 7.5 billion yuan has attracted significant market attention, highlighting a trend among A-share companies, including those on the Sci-Tech Innovation Board, to utilize idle funds for cash management [1][2]. Group 1: Idle Fund Management in A-Share Market - Over the past three years, more than 110 A-share listed companies have reported annual idle cash management exceeding 5 billion yuan, including 14 companies from the Sci-Tech Innovation Board [1]. - Among the 12 Sci-Tech Innovation Board companies managing idle funds, 6 have amounts exceeding 5 billion yuan, with Moer Thread managing 7.5 billion yuan and Huahong managing 21 billion yuan [2]. Group 2: Regulatory Framework and Recent Changes - The China Securities Regulatory Commission (CSRC) has established regulations for the management of idle fundraising, which were revised and upgraded in June 2025 to enhance oversight [6][10]. - The latest regulations stipulate that idle funds can be managed through dedicated accounts, ensuring that cash management does not interfere with the normal investment plans of the fundraising [10]. Group 3: Industry Practices and Investor Concerns - Companies in the high-end computing sector often face long technical cycles, making the use of idle funds for cash management a common practice [4]. - There is a call from investors and industry insiders for more detailed disclosures regarding the management of idle funds to enhance transparency and protect investor interests [1][12].